Current Report Filing (8-k)
August 16 2021 - 6:59AM
Edgar (US Regulatory)
0001533998
false
0001533998
2021-08-16
2021-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 16, 2021 (August 16, 2021)
DARIOHEALTH CORP.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-37704
|
|
45-2973162
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
142 W. 57th St., 8th
Floor
New York, New York
10019
(Address of Principal
Executive Offices)
(646) 665-4667
(Issuer’s telephone
number)
(Former name or former
address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which
registered
|
Common Stock, par value $0.0001 per share
|
|
DRIO
|
|
The Nasdaq Capital Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results
of Operations and Financial Condition
On August 16, 2021, DarioHealth
Corp. (the “Company”) issued a press release announcing the Company’s financial and operating results and recent highlights
for the quarter and six months ended June 30, 2021. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
In accordance with General
Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not
be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: August 16, 2021
|
DARIOHEALTH CORP.
|
|
|
|
|
|
By:
|
/s/ Zvi Ben David
|
|
|
Name: Zvi Ben David
Title: Chief Financial Officer, Treasurer and Secretary
|
DarioHealth (NASDAQ:DRIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
DarioHealth (NASDAQ:DRIO)
Historical Stock Chart
From Apr 2023 to Apr 2024